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Abstract
Introduction: Systemic lupus erythematosus (SLE) is a complex, multifactor
autoimmune disease. The studies on aetiopathogenesis of autoimmune diseases
focus on the impact the genetically conditioned impairment of xenobiotic
metabolism may exert. The knowledge of oxidation polymorphism in the course
of SLE may be helpful in choosing more efficient and safer therapy. We
determined whether there was an association between susceptibility to SLE and
particularly to CYP2D6 genotypes. 
Material and methods: The study was carried out in 60 patients with SLE and
129 healthy volunteers and all the subjects were of Polish origin. The samples
were analysed for two major defective alles for CYP2D6 – CYP2D6*3 and
CYP2D6*4 and one wild -type allele CYP2D6*1-by the polymerase chain reaction
fragment length polymorphism (PCR-RFLP) metod with DNA extracted from
peripheral blood.
Results: No statistically significant differences in the incidence of CYP2D6
genotypes between the studied groups were found (p = 0.615). Risk (OR) of SLE
development was 1.03 for the carriers of CYP2D6*3 allele and 1.48 for the
subjects with CYP2D6*4 allele; but it was not statistically significant. 
Conclusions: Increased occurrence of mutant alleles of the CYP2D6 gene in SLE
patients and the calculated OR values could suggest the effect of these
mutations on increased SLE development. 
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Introduction
In recent years, numerous observations have elucidated the role of
hereditary factors in susceptibility to some diseases. Systemic lupus
erythematosus (SLE) is one of them. 
Systemic lupus erythematosus is a chronic, systemic autoimmune
disease with a complex pathogenesis involving multiple genetic and
environmental factors. Systemic lupus erythematosus predominantly
affects women in childbearing age. The disease is characterized by
autoantibody production, abnormalities in the immune-inflammatory
system function and inflammatory manifestation in several organs [1]. The
aetiology of SLE is still unclear. The pathogenic process involves a complex
interaction between environmental agents, hor  mones, immunomodulatory
factors and disease susceptibility genes that predispose to SLE. The disease
becomes symptomatic when the total of effects of different factors exceeds
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a certain threshold, which causes an improper
production of autoantibodies [2]. The genetic
background of SLE is thought to be complex and
involves multiple genes encoding different
molecules with significant functions in immune
system regulation [1, 3-5]. The group of candidate
genes includes those encoding the activity 
of enzymes that metabolise xenobiotics.
Environmental factors have been known to play
a crucial role in autoimmune diseases; therefore
numerous studies are being performed whose aim
is to elucidate the effect of xenobiotics on the
occurrence of autoimmune processes leading to SLE
development. Many xenobiotics may induce alte  -
rations in the chromosomal structure, e.g., drugs,
pesticides, fungicides, or substances causing
environmental pollution [6]. The studies on aetio  -
pathogenesis of autoimmune diseases focus on the
impact the genetically conditioned impairment of
xenobiotic metabolism may exert. 
Many of these enzymes, including CYP2D6, play
an instrumental role in the oxidation of multiple
drugs and in the activation and deactivation of
environmental xenobiotics such as carcinogens and
toxic substances [6-8]. The CYP2D6 gene is localized
on chromosome 22q13.1 [9]. The CYP2D6 (also
called debrisoquine/sparteine hydroxylase) poly  -
morphism was described in the 1970s while
studying the metabolism of debrisoquine and
sparteine [10]. Two phenotypically distinct groups
were distinguished based on the capability to
oxidise debrisoquine or sparteine to hydro  xy  -
metabolites in the human population: persons
actively oxidizing the above-mentioned compounds
– extensive metabolisers (EM) – and subjects who
oxidize poorly, to a minimum degree – poor
metabolisers (PM). In general, PM patients are
characterized by reduced or no metabolic activity
of CYP2D6 enzyme compared to EM patients, who
have normal metabolic activity of CYP2D6 [11]. The
polymorphism of the CYP2D6 gene has been
relatively well explained, and more then 90 allelic
variants of the CYP2D6 gene have been described.
(http://www.imm.ki.se/CYPalleles). These variants
result from point mutations, deletions or additions,
gene rearrangements and deletion or duplication
of the entire gene and result in an increase,
reduction, or a complete loss of activity [6]. In
general, 71% of CYP2D6 alleles in Caucasians are
functional alleles, while non-functional alleles
account for 26%. The non-functional CYP2D6*4
(allele frequency 20%) is carried by 75% of CYP2D6
poor metabolizers, while CYP2D6*3 is carried by 
1-2% of them [12, 13]. The polymorphisms of the
CYP2D6 gene can result in defective or increased
enzyme activity and CYP2D6 genotypes usually
exhibit large inter-ethnic differences [8]. The
knowledge of oxidation polymorphism in the course
of SLE may be helpful in choosing more efficient
and safer therapy, particularly in the case of
a disease involving various organs and treated with
drugs belonging to diverse therapeutic groups.
Studying gene-environment interactions in
relation to the risk of SLE may be valuable because
positive findings would clearly implicate the
disease-causing exposures, clarify SLE aetiology and
point to environmental modifications for disease
prevention. 
Despite the important role that CYP2D6 plays in
detoxifying xenobiotics, few studies have
investigated its function in SLE pathology [14, 15].
Our study is the first that estimates the distribution
of CYP2D6 genotypes in patients suffering from
systemic lupus erythematosus from Poland.
The aim of our study was to analyse the CYP2D6
alleles, to assess the distribution of the genotypes
in 60 patients with SLE and to establish whether
there is any correlation between CYP2D6 genotype
and SLE development.
Material and methods
The study was carried out in 60 patients with
SLE diagnosed according to the criteria of the
American College of Rheumatology [16]. The group
of patients with SLE consisted of 54 women and 6
men (age range 17-76 years, mean 42 ±12.48
years).The patients were hospitalized at the
Department of Dermatology and Paediatric
Dermatology, Military-Medical Faculty, Medical
University of Lodz, Poland, and all the subjects were
of Polish origin. The control group consisted of 
129 volunteers (80 women and 49 men) aged 
18-73 years (mean age 41.3 ±15.41 years) with no
acute or chronic autoimmune diseases. The local
ethics committee on human research approved the
study, and informed consent was obtained from all
patients.
The samples were analysed for two major
defective alleles for CYP2D6  –  CYP2D6*3  and
CYP2D6*4 – and one wild-type allele CYP2D6*1 by
the polymerase chain reaction fragment length
polymorphism (PCR-RFLP) method according to the
procedure proposed by Smith et al. [17]. The
application of the PCR-RFLP method allowed us to
isolate two phenotypically distinct oxidation 
groups of subjects, i.e. poor metabolizers (PM),
homozygotes possessing two mutated alleles:
CYP2D6*3 and CYP2D6*4; extensive metabolizers
(EM), heterozygotes possessing one wild-type allele
(CYP2D6*1) and one mutated allele (CYP2D6*3,
CYP2D6*4); and homozygotes possessing two wild
alleles (CYP2D6*1) in their loci.
Genomic DNA was isolated from peripheral blood
leukocytes. A 10 ml venous blood sample was
obtained from each patient and control and was
stored in EDTA blood containers at –20°C. Genomic
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DNA was subjected to amplification using PCR with
a pair of synthetic oligonucleotides, separately for
the  CYP2D6*3  and  CYP2D6*4  mutations. PCR
amplification was performed in a total reaction
volume of 50 μl containing 0.2-0.5 μg genomic DNA,
1U Taq Polymerase (Invitrogen USA), 1 × PCR buffer
(20 mM Tris-HCl, pH 8.4, 50 mM KCl), 1.5 mM MgCl2,
0.2 mM of each dNTP (Fermentas, Germany), 5%
DMSO (Sigma, USA) and 250 nmol of each primer
(Oligo IBB PAN, Poland). PCR amplification was
conducted in an Eppendorf Mastercycler Personal
thermal cycler (Germany). The obtained product of
amplification was subjected to digestion by
restriction enzymes after control assessment in 2%
agarose gel. The restriction endonucleases BstN 1
(New England BioLabs, USA) (CYP2D6*4) and HpaII
(Invitrogen USA) (CYP2D6*3) were used to detect
the presence or absence of mutations at the
position G 1934 A and A 2637 deletion, respectively.
Separation of the obtained digestion products was
conducted using electrophoresis in 8% poly  -
acrylamide gel. The obtained bands corres  ponding
to particular DNA fragments following staining of
the polyacrylamide gel with ethidium bromide were
analysed in UV light. 
The frequency distribution of CYP2D6 genotypes
in SLE patients was compared with healthy subjects
and analysed statistically using the χ2 test alone
and with the Yates modification for small groups.
Odds ratio (OR) with 95% confidence interval 
(95% CI) was calculated using the computer
program Statistica 6.0.
Results
We determined whether there were any
associations between susceptibility to SLE and
particular  CYP2D6 genotypes. Subjects were
assigned to three different classes of overall
genotypes (PM: CYP2D6*3/CYP2D6*4 or CYP2D6*4/
CYP2D6*4, heterozygous EM: CYP2D6*1/CYP2D6*4
and homozygous EM: CYP2D6*1/CYP2D6*1) on the
basis of PCR results. 
The frequency distribution of oxidation geno  -
types determining poor and extensive metabolizers
in patients suffering from systemic lupus erythema  -
tosus and in controls is shown in Table I. There was
no significant difference in the frequency of
distribution of poor and extensive genotypes
between patients with SLE and the control group.
The incidences of the three possible genotypes in
the SLE population and in the controls as well as the
OR SLE development are summarized in Table II.
Among 60 patients with SLE, EM homozygotes of
the  CYP2D6*1 allele with CYP2D6*1/CYP2D6*1
genotype accounted for 45%, and heterozygotes
with CYP2D6*1/CYP2D6*4 genotype accounted for
41.67%. Seven (11.67%) people were PM with
CYP2D6*3/CYP2D6*4 or CYP2D6*4/CYP2D6*4 geno  -
type. Results obtained in the SLE group did not
differ significantly from those in the control group.
Frequency of CYP2D6 gene alleles was compared
between SLE patients and the control group.
Differences in allele frequency between the groups
were not statistically significant (Table III). 
Discussion
The human organism is constantly exposed to
harmful exogenous factors (xenobiotics) including
drugs and carcinogenic compounds that can induce
development of a large number of diseases. The
Group  Number  Poor  Extensive 
of patients metabolizers metabolizers 
(PM)( E M)
SLE  60 7 (11.7%) 53 (88.3%)
Control  129 12 (9.3%) 117 (90.7%)
Table I. Distribution of poor and extensive genotypes
in patients with SLE and in the controls
χ2 = 0.253, p = 0.615, p – statistical significance (p < 0.05), χ2 – test χ2
comparison between 2 groups of patients with SLE and control subjects
CYP2D6 Patients with SLE (n = 60) Control group (n = 129) Value  OR (95% CI)
N % N % of p
Extensive Homozygous:
metabolizers  CYP2D6*1/CYP2D6*1 27 45 74 57.4 1.112 0.61 (0.32-1.12)
(EM) Heterozygous:
CYP2D6*1/CYP2D6*3 1 1.66 4 3.1 0.571 0.53 (0.06-4.85)
CYP2D6*1/CYP2D6*4 25 41.67 39 30.2 1.122 1.65 (1.14-3.09)
Total: 53 88.33 117 90.7 0.615 0.78 (0.29-2.07)
Poor  CYP2D6*3/CYP2D6*4 1 1.67 0 – 0.141 –
metabolizers CYP2D6*4/CYP2D6*4 6 10 12 9.3 0.879 1.08 (0.34-3.44)
(PM)
Total: 7 11.67 12 9.3 0.615 1.29 (0.48-3.46)
Table II. Frequency distribution of homozygous EM and PM and heterozygous EM patients with SLE and controls
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processes of biotransformation in the organism are
multidirectional and xenobiotics can be transformed
into active or inactive metabolites via the oxidative
route. They can also be transformed into harmful
compounds with a potentially pathogenic action.
The enzymatic system associated with the liver
microsomal fraction with cytochrome P-450 as its
fundamental element is responsible for xenobiotic
oxidation. At present, the role of cytochrome P-450
and its isoforms in regulating not only the
processes of drug metabolism and immune
reactions but also in activating toxic substances has
aroused great attention in the literature.
Cytochrome P-450 enzymes show genetic
polymorphism, which contributes to marked inter-
individual differences in drug responses. Exa  -
minations of the oxidative genotype or phenotype
have been performed in order to identify the
oxidative polymorphisms [18, 19]. Differences
among individuals in drug responses due to
mutations in the CYP2D6 gene that is involved in
the metabolism of xenobiotics, including a number
of drugs with a wide therapeutic use, were
discovered as early as in the 1970s. Genetically
determined oxidative polymorphism can affect not
only drug efficacy but may also be a factor
predisposing to disease development. 
In the present study we tried to answer the
question whether any associations exist between
genetically determined activity of CYP2D6 enzyme
and SLE development in the Polish population.
There are numerous reports demonstrating the role
of oxidative polymorphism in predisposing towards
development of tumour diseases, allergy or
psychiatric and neurological syndromes. Studies
evaluating a predisposition towards tumour
diseases have been carried out for a long time and
predominantly concern tumours of the lungs,
genitourinary tract and prostate as well as
myeloblastic leukaemia. Those studies demonstrate
that subjects who are extensive or ultra-rapid
metabolizers account for the majority of patients
with tumour diseases [20-24]. Studies on oxidative
polymorphism have also been conducted in
patients with Parkinson’s or Alzheimer’s diseases;
however, the results are conflicting [13, 25, 26].
There are few reports in the available literature
that concern the role of xenobiotic metabolizing
enzyme polymorphism in autoimmune diseases
[14, 15, 27]. However, a report about the association
of CYP2D6 gene with SLE is still unavailable in
Poland. Systemic lupus erythematosus is a model
auto  immune disease that is characterized by
increased production of autoantibodies against
different antigens. Contemporary medicine is able
to alleviate the symptoms only to a limited extent,
with no possibility of complete recovery. The reason
for that is still insufficient knowledge on SLE
aetiopatho  genesis, but there is evidence for
a crucial role of genetic factors besides immuno  -
modulatory and environmental factors in the
disease development.
The first reports concerning associations
between oxidative genotype and SLE were pub  -
lished in 1998. A study that was conducted among
69 patients with SLE and 514 healthy Caucasian
volunteers showed that the incidence of the
CYP2D6*4 allele was significantly higher in the
group of SLE patients compared with the control
group (28.3% and 18.6%, respectively). However,
the difference was not statistically significant. It has
been observed that the CYP2D6*4 allele occurred
more frequently in SLE patients in whom renal
involvement and haematological abnormalities had
been established [15]. CYP2D6 polymorphism was
also the subject of a study by Kortunay et al.
However, the authors failed to show any association
between the CYP2D6 genotype and the risk of
developing SLE [14]. 
In our own studies we observed a higher
proportion of subjects who were characterized by
poor metabolism among SLE patients in
comparison with the healthy ones. It has been
shown that the frequency of genotypes for the
poor and extensive oxidation in the group of SLE
patients reached 11.7% and 88.3% respectively
compared with 9.3% for poor metabolizers and
90.7% for extensive metabolizers in the control
group. No statistically significant differences in the
incidence of CYP2D6 genotypes for poor and
extensive oxidation between the studied groups
were found (p = 0.615). CYP2D6*1/CYP2D6*1 and
CYP2D6*1/CYP2D6*4 genotypes occurred most
frequently in the group of SLE patients, whereas
CYP2D6*1/CYP2D6*1 genotype was predominant
among the controls. Relative risk of developing SLE,
expressed as the odds ratio (OR), was not
statistically significantly higher for the carriers of
the particular genotypes. 
The wild-type allele CYP2D6*1 was found most
frequently (66.6%) in the group of patients with
SLE. Both mutant alleles, i.e. CYP2D6*3  and
CYP2D6*4, accounted for 1.7% and 31.6%, res  -
pectively, and these values were not statistically
Allele CYP2D6*1 CYP2D6*3 CYP2D6*4
Patients with  80  2  38 
SLE (%) (66.6%) (1.7%) (31.6%)
Controls (%) 191  4  63 
(74%) (1.6%) (24.4%)
OR (95% CI) 0.7  1.08  1.43 
(0.44-1.11) (0.19-5.96) (0.89-2.29)
Table III. Frequency of CYP2D6 alleles in patients with
SLE and controls 
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significantly different from the results obtained both
in the control group (74%, 1.6% and 24.4%
respectively) and the results in the Caucasian
population (70%, 2% and 20% respectively) [23, 28,
29]. Relative risk of SLE development was 1.08-fold
higher for the carriers of the CYP2D6*3 allele and
1.43-fold higher for the subjects with the CYP2D6*4
allele; however, the risk was not statistically
significantly higher. Increased occurrence of mutant
alleles of the CYP2D6 gene in SLE patients and the
calculated OR values could suggest the effect of
these mutations on increased SLE development.
Continuing the studies in a larger group of SLE
patients is likely to provide confirmation of the
observations and a more precise insight into the
nature of the relationships between genetically
determined metabolic factors and SLE development. 
There are reports in the literature on the impact
of the polymorphisms of other cytochrome P-450
enzymes on the risk of SLE development. Results
obtained from the studies on the CYP1A1 gene
implicate that the presence of polymorphisms in
this gene might be a risk factor for SLE development
and a predictor of renal involvement [30]. 
Knowledge of the genetically conditioned
differences in oxidation processes as well as
determination of the incidences of the principal
mutations in the cytochrome P-450 isoenzyme
CYP2D6 gene seems to be a vital clinical issue.
Pharmacogenetic studies provide the possibility of
establishing one of the potential reasons for the risk
of developing autoimmune diseases, including SLE.
Results from the studies that have been conducted
so far allow the statement that oxidative poly  -
morphisms are not a risk factor for developing SLE.
However, it seems that determination of CYP2D6
genotype in SLE patients is of significant clinical
value since SLE is a disease that involves many
organs and the treatment may require application
of drugs that are subject to oxidation. Therapeutic
effects with drugs subjected to oxidation are less
satisfactory in extensive metabolizers compared
with persons who are poor metabolizers. Relapses
occur more frequently and remissions are quite rare
among subjects who are extensive metabolizers.
Treatment seems more effective in poor meta  -
bolizers but serious side effects that are associated
with applying standard doses of drugs are
frequently observed. 
An examination of the oxidative genotype or
phenotype allows individualization of pharmaco  -
therapy. Knowledge of the oxidative polymorphism
and its relationship with SLE may contribute to
a safer and more efficient therapy since the disease
is multiorgan and often requires drugs that belong
to a variety of therapeutic groups.
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